Lung gas volumes and expiratory time constant in immature newborn rabbits treated with natural or synthetic surfactant or detergents.
Immature newborn rabbits delivered at a gestational age of 27 days were tracheotomized and treated, via the tracheal cannula, with clinically recommended doses of natural or synthetic surfactant (Curosurf and Exosurf, respectively). Littermates received 0.1% tyloxapol, 5% Tween 20, or saline. The dose volume of Curosurf was 2.5 ml/kg, that of the other materials 5 ml/kg. Animals were kept in a multiplethysmograph system and ventilated for 30 min with a standardized sequence of insufflation pressures. End-expiratory lung gas volume was calculated at the end of the experiment from measurements of lung weight and total lung volume. Tidal volumes were significantly improved in all groups of animals receiving surfactant or detergents. However, expiratory time constant (determined from the tidal volume tracing) was significantly longer, and end-expiratory gas volume significantly larger, in animals treated with Curosurf than in those receiving Exosurf or detergents. These differences were confirmed by semiquantitative evaluation of alveolar air expansion in histological sections. In addition, airway epithelial necrosis was reduced in animals receiving Curosurf, Exosurf, or Tween 20, but not in animals treated with tyloxapol. The discrepancy between improvements in tidal volume, expiratory time constant, and end-expiratory gas volume reflects failure of lung stabilization in animals treated with Exosurf or detergents, probably due to absence of specific hydrophobic proteins in the synthetic products.
Bongrani
S
S
Karolinska Institute, Research Unit for Experimental Perinatal Pathology, Karolinska Hospital, Stockholm, Sweden.
Fornasier
M
M
Papotti
M
M
Razzetti
R
R
Robertson
B
B
D000818:Animals; D000831:Animals, Newborn; D001688:Biological Products; D003902:Detergents / Q000008:administration & dosage*; D004338:Drug Combinations; D005233:Fatty Alcohols / Q000008:administration & dosage*; D005325:Fetal Organ Maturity; D008168:Lung / Q000187:drug effects / Q000196:embryology / Q000503:physiopathology*; D010743:Phospholipids; D010767:Phosphorylcholine; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011663:Pulmonary Surfactants / Q000008:administration & dosage*; D011817:Rabbits; D012129:Respiratory Function Tests
D001688:Biological Products; D003902:Detergents; D004338:Drug Combinations; D005233:Fatty Alcohols; D010743:Phospholipids; D011663:Pulmonary Surfactants; D010767:Phosphorylcholine; D011092:Polyethylene Glycols; C047049:dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination; C068291:poractant alfa